Tetraspanin 8 Monoclonal Antibodies for Exosome Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for anti-TSPAN8 antibodies with unique genetic and amino acid structures, including specific binding and functional characteristics, to effectively diagnose various diseases and utilize in biomedical techniques, as existing antibodies may not adequately address the role of Tetraspanin 8 in cancer and other biological processes.
Innovation Solution
Development of monoclonal antibodies and hybridoma cell lines that specifically bind to the native, non-reduced Tetraspanin 8 protein, including the production of murine monoclonal antibodies like BT-43, which recognize human TSPAN8 in its native form, and the creation of kits for exosome purification using labeled antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibodies are used, then general detection is possible, but specific binding characteristics and functional properties for diagnosing cancer and other diseases are insufficient
Solution Approach 1:
The patent develops multiple monoclonal antibody variants (different hybridoma clones) with distinct binding characteristics and functional properties. Each clone produces antibodies with unique genetic and amino acid structures that provide different binding affinities and specificities to TSPAN8, enabling tailored selection for specific diagnostic and therapeutic applications
Solution Approach 2:
The invention segments the antibody development into distinct hybridoma clones (e.g., BT-43, BT-44, BT-45, BT-46, BT-47, BT-48, BT-49, BT-50, BT-51, BT-52, BT-53, BT-54, BT-55, BT-56, BT-57, BT-58, BT-59, BT-60, BT-61, BT-62, BT-63, BT-64, BT-65, BT-66, BT-67, BT-68, BT-69, BT-70, BT-71, BT-72, BT-73, BT-74, BT-75, BT-76, BT-77, BT-78, BT-79, BT-80, BT-81, BT-82, BT-83, BT-84, BT-85, BT-86, BT-87, BT-88, BT-89, BT-90, BT-91, BT-92, BT-93, BT-94, BT-95, BT-96, BT-97, BT-98, BT-99, BT-100), each with unique binding characteristics, allowing selection of optimal clones for specific applications rather than relying on a single antibody type
2Manufacturing precision
If monoclonal antibodies are developed with unique genetic and amino acid structures, then specific binding characteristics are improved, but development complexity and time increase
Solution Approach 1:
The patent employs preliminary immunization of animals with TSPAN8 antigen followed by systematic hybridoma generation and screening processes. Multiple clones are developed in advance with characterized binding properties, creating a ready-to-use panel of monoclonal antibodies that can be directly applied to specific diagnostic and therapeutic needs without requiring de novo development
Solution Approach 2:
The invention systematically varies genetic and amino acid parameters across different hybridoma clones to generate antibodies with distinct binding characteristics. By changing the genetic makeup and amino acid sequences through different immunization protocols and hybridoma selections, the patent achieves high specificity while managing development complexity through structured parameter variation
3Measurement precision
If antibodies recognize native non-reduced TSPAN8 protein, then diagnostic accuracy for cancer progression and metastasis is improved, but detection methodology complexity increases
Solution Approach 1:
The patent develops antibodies with specificity tailored to particular epitopes and conformational states of TSPAN8. Different monoclonal clones recognize different regions and structural states of the protein, allowing selection of antibodies optimized for detecting native non-reduced TSPAN8 in specific diagnostic contexts such as cancer progression and metastasis detection
Solution Approach 2:
The invention creates simplified detection methodologies by using monoclonal antibodies that specifically recognize native TSPAN8 conformations. These antibodies serve as precise molecular copies or proxies for detecting the native protein state in complex biological samples, enabling accurate detection without requiring complex native protein reconstruction or multiple processing steps
Data Source
AI summary
The present invention is directed to a monoclonal antibody that recognizes human TSPAN8 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and exosome purification kits using the antibody.